Nicotine and Cognitive Decline: Could This Molecule Protect the Aging Brain?
The epidemiological evidence is consistent: smokers have lower rates of Parkinson's disease. The mechanism appears to be nicotine's neuroprotective effect. Research on nicotine for cognitive decline is ongoing. The implications are ethically complex.
The Parkinson's-smoking inverse association is one of the strongest in epidemiology. Smokers have a 50% lower risk. The mechanism: nicotine's anti-inflammatory and neuroprotective effects on dopaminergic neurons. **Nicotine is being investigated for mild cognitive impairment and Alzheimer's disease—not as a smoking product, but as a purified pharmaceutical. The research is preliminary but promising. The ethical complexity: a molecule that contributes to addiction when delivered via cigarettes may, in a different form, protect the aging brain.**
